Value proposition

Creating class-leading ADCs with enhanced tumor specificity

Through our highly experienced ADC Research & Development Team, we are building a pipeline of class-leading ADCs with superior therapeutic index (TI) for difficult-to-treat cancers.

Our approach is to develop the best ADC for any given target or tumor sub-type rather than 'technology-driven ADCs'.

All our ADCs incorporate tumor-selective release & activation of the most relevant payload according to mechanism, optimizing anti-cancer efficacy and enhancing patient safety.





Antibody-Drug Conjugates, PermaLink™, Conjugation Chemistry, Cancer research, ADCs, Drug Development, Therapeutics, Antibodies, Toxins, Cancer Treatment, ADC Stability, Antibody Drug Conjugate, Drug Discovery, Biotechnology, Preclinical, Bioconjugation, Organic Synthesis, Clinical, Cell Biology, Chemistry, and Licencing